BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dominguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation. 2000;70:1244-1247. [PMID: 11063349 DOI: 10.1097/00007890-200010270-00021] [Cited by in Crossref: 97] [Cited by in F6Publishing: 86] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Niemczyk M, Żegarska J, Pawłowska M, Wyzgał J, Ciszek M, Pączek L. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor. Transplant Immunology 2009;20:139-42. [DOI: 10.1016/j.trim.2008.09.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
2 Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007;67:369-91. [PMID: 17335296 DOI: 10.2165/00003495-200767030-00004] [Cited by in Crossref: 152] [Cited by in F6Publishing: 126] [Article Influence: 10.9] [Reference Citation Analysis]
3 Lei M, Wang CJ, Yu F, Xie K, Lin SH, Xu F. Different intensity of autophagy regulate interleukin-33 to control the uncontrolled inflammation of acute lung injury. Inflamm Res 2019;68:665-75. [PMID: 31147742 DOI: 10.1007/s00011-019-01250-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
4 Saunders RN, Bicknell GR, Nicholson ML. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 2003;75:772-80. [PMID: 12660500 DOI: 10.1097/00007890-200303270-00008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
5 Neofytos D, Hirzel C, Boely E, Lecompte T, Khanna N, Mueller NJ, Boggian K, Cusini A, Manuel O, van Delden C; Swiss Transplant Cohort Study. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort. Transpl Infect Dis 2018;20:e12984. [PMID: 30155950 DOI: 10.1111/tid.12984] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
6 Martínez-Mier G, Méndez-López MT, Estrada-Oros J, Budar-Fernandez LF, Soto-González JI, Méndez-Machado GF, Viñas Dozal JC. Conversion from calcineurin inhibitor to sirolimus for renal function deterioration in kidney allograft recipients. Arch Med Res 2006;37:635-8. [PMID: 16740435 DOI: 10.1016/j.arcmed.2005.12.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
7 Morath C, Schwenger V, Ksoll-Rudek D, Sommerer C, Beimler J, Schmidt J, Zeier M. Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors. Transplant Proc. 2007;39:99-102. [PMID: 17275483 DOI: 10.1016/j.transproceed.2006.10.219] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
8 van Gelder T, ter Meulen CG, Hené R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003;75:788-91. [PMID: 12660502 DOI: 10.1097/01.TP.0000056639.74982.F9] [Cited by in Crossref: 104] [Cited by in F6Publishing: 10] [Article Influence: 5.8] [Reference Citation Analysis]
9 Wang EH, Partovi N, Levy RD, Shapiro RJ, Yoshida EM, Greanya ED. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past. Transpl Infect Dis. 2012;14:519-525. [PMID: 22571389 DOI: 10.1111/j.1399-3062.2012.00740.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 7.3] [Reference Citation Analysis]
10 Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED. Absence of Proteinuria Predicts Improvement in Renal Function After Conversion to Sirolimus-based Immunosuppressive Regimens in Lung Transplant Survivors With Chronic Kidney Disease. The Journal of Heart and Lung Transplantation 2009;28:564-71. [DOI: 10.1016/j.healun.2009.03.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
11 Gutiérrez-dalmau A, Sánchez-fructuoso A, Sanz-guajardo A, Mazuecos A, Franco A, Rial M, Iranzo P, Torregrosa J, Oppenheimer F, Campistol J. Efficacy of Conversion to Sirolimus in Posttransplantation Kaposi’s Sarcoma. Transplantation Proceedings 2005;37:3836-8. [DOI: 10.1016/j.transproceed.2005.10.076] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
12 Dittrich E, Schmaldienst S, Soleiman A, Horl WH, Pohanka E. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transplant Int 2004;17:215-20. [DOI: 10.1111/j.1432-2277.2004.tb00431.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 65] [Article Influence: 6.1] [Reference Citation Analysis]
13 Chueh SC, Kahan BD. Clinical application of sirolimus in renal transplantation: an update. Transpl Int. 2005;18:261-277. [PMID: 15730485 DOI: 10.1111/j.1432-2277.2004.00039.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
14 Ahn SH, Min S, Min SI, Kim SY, Kim SJ, Ha J. Oral Ulceration an Overlooked Complication of Mycophenolate Mofetil in a Renal Transplant Recipient. J Korean Soc Transplant 2011;25:113. [DOI: 10.4285/jkstn.2011.25.2.113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Diekmann F, Waiser J, Fritsche L, Dragun D, Neumayer HH, Budde K. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. Transplant Proc. 2001;33:3234-3235. [PMID: 11750386 DOI: 10.1016/s0041-1345(01)02375-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Fricain J, Cellerié K, Sibaud V, Catros S, Taïeb A, Merville P. Ulcérations buccales chez les patients transplantés rénaux traités par sirolimus. Annales de Dermatologie et de Vénéréologie 2008;135:737-41. [DOI: 10.1016/j.annder.2008.07.055] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
17 Walters HE, Cox LS. mTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases. Int J Mol Sci 2018;19:E2325. [PMID: 30096787 DOI: 10.3390/ijms19082325] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
18 Johnson RW. Sirolimus (Rapamune) in renal transplantation. Curr Opin Nephrol Hypertens 2002;11:603-7. [PMID: 12394605 DOI: 10.1097/00041552-200211000-00006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
19 Mulay AV, Cockfield S, Stryker R, Fergusson D, Knoll GA. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation. 2006;82:1153-1162. [PMID: 17102766 DOI: 10.1097/01.tp.0000237101.58974.43] [Cited by in Crossref: 85] [Cited by in F6Publishing: 73] [Article Influence: 6.1] [Reference Citation Analysis]
20 Neff GW, Ruiz P, Madariaga JR, Nishida S, Montalbano M, Meyer D, Levi DM, Tzakis AG, O'brien CB. Sirolimus-Associated Hepatotoxicity in Liver Transplantation. Ann Pharmacother 2004;38:1593-6. [DOI: 10.1345/aph.1e165] [Cited by in Crossref: 42] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
21 Khanna A, Plummer M, Bromberek K, Woodliff J, Hariharan S. Immunomodulation in stable renal transplant recipients with concomitant tacrolimus and sirolimus therapy. Med Immunol 2002;1:3. [PMID: 12495444 DOI: 10.1186/1476-9433-1-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
22 Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N, Granucci L, Major C, Costaglio C, Sanchez J, Orlandi P, Salvatierra O. PROMISING EARLY OUTCOMES WITH A NOVEL, COMPLETE STEROID AVOIDANCE IMMUNOSUPPRESSION PROTOCOL IN PEDIATRIC RENAL TRANSPLANTATION1: . Transplantation 2001;72:13-21. [DOI: 10.1097/00007890-200107150-00006] [Cited by in Crossref: 177] [Cited by in F6Publishing: 146] [Article Influence: 8.9] [Reference Citation Analysis]
23 Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004;65:1262-71. [PMID: 15086465 DOI: 10.1111/j.1523-1755.2004.00498.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 4.5] [Reference Citation Analysis]
24 Macdonald AS. Use of mTOR inhibitors in human organ transplantation. Expert Review of Clinical Immunology 2014;3:423-36. [DOI: 10.1586/1744666x.3.3.423] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Li JYZ, Yong TY, Grove DI, Coates PTH. Late-onset and atypical presentation of Pneumocystis carinii pneumonia in a renal transplant recipient. Clin Exp Nephrol 2009;13:92-5. [DOI: 10.1007/s10157-008-0079-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
26 Aliabadi AZ, Pohanka E, Seebacher G, Dunkler D, Kammerstätter D, Wolner E, Grimm M, Zuckermann AO. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant. 2008;8:854-861. [PMID: 18261172 DOI: 10.1111/j.1600-6143.2007.02142.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 4.7] [Reference Citation Analysis]
27 Lindenfeld JA, Simon SF, Zamora MR, Cool CD, Wolfel EE, Lowes BD, Ireland N, Keller K, Frisk R, Stepien L, Cleveland JC, Zolty R. BOOP is Common in Cardiac Transplant Recipients Switched from a Calcineurin Inhibitor to Sirolimus. Am J Transplant 2005;5:1392-6. [DOI: 10.1111/j.1600-6143.2005.00849.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
28 Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrology Dialysis Transplantation 2006;21:562-8. [DOI: 10.1093/ndt/gfi336] [Cited by in Crossref: 60] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
29 El-sabrout R, Weiss R, Butt F, Delaney V, Qadir M, Hanson P, Butt K. Rejection-free protocol using sirolimus-tacrolimus combination for pediatric renal transplant recipients. Transplantation Proceedings 2002;34:1942-3. [DOI: 10.1016/s0041-1345(02)03130-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
30 Bechman K, Galloway JB, Winthrop KL. Small-Molecule Protein Kinases Inhibitors and the Risk of Fungal Infections. Curr Fungal Infect Rep 2019;13:229-43. [DOI: 10.1007/s12281-019-00350-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
31 Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrology Dialysis Transplantation 2005;20:2517-23. [DOI: 10.1093/ndt/gfh957] [Cited by in Crossref: 137] [Cited by in F6Publishing: 119] [Article Influence: 8.6] [Reference Citation Analysis]
32 Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatric Transplantation 2006;10:565-9. [DOI: 10.1111/j.1399-3046.2006.00515.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
33 Molinari M, Berman K, Meeberg G, Shapiro JA, Bigam D, Trotter JF, Kneteman N. Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transpl Int. 2010;23:155-168. [PMID: 19765266 DOI: 10.1111/j.1432-2277.2009.00969.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
34 Watson CJE, Firth J, Williams PF, Bradley JR, Pritchard N, Chaudhry A, Smith JC, Palmer CR, Bradley JA. A Randomized Controlled Trial of Late Conversion from CNI-Based to Sirolimus-Based Immunosuppression Following Renal Transplantation. Am J Transplant 2005;5:2496-503. [DOI: 10.1111/j.1600-6143.2005.01055.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 93] [Article Influence: 7.1] [Reference Citation Analysis]
35 Wu MS, Hung CC, Chang CT. Renal calcium handling after rapamycin conversion in chronic allograft dysfunction. Transpl Int 2006;19:140-5. [PMID: 16441363 DOI: 10.1111/j.1432-2277.2005.00251.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
36 Bäckman L, Reisaeter AV, Wramner L, Ericzon BG, Salmela K, Brattström C. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus. Clin Transplant 2006;20:336-9. [PMID: 16824151 DOI: 10.1111/j.1399-0012.2006.00489.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
37 Haydar AA, Denton M, West A, Rees J, Goldsmith DJ. Sirolimus-induced pneumonitis: three cases and a review of the literature. Am J Transplant 2004;4:137-9. [PMID: 14678046 DOI: 10.1046/j.1600-6135.2003.00292.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
38 King-biggs MB, Dunitz JM, Park SJ, Kay Savik S, Hertz MI. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003;75:1437-43. [DOI: 10.1097/01.tp.0000064083.02120.2c] [Cited by in Crossref: 137] [Cited by in F6Publishing: 24] [Article Influence: 7.6] [Reference Citation Analysis]
39 Wilkinson A. Progress in the clinical application of immunosuppressive drugs in renal transplantation: . Current Opinion in Nephrology and Hypertension 2001;10:763-70. [DOI: 10.1097/00041552-200111000-00006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
40 Leth S, Jensen-Fangel S, Østergaard L, Rostved AA, Jespersen B, Søgaard OS. Pneumocystis jirovecii pneumonia in patients with end-stage renal disease: a comparison with the general population. Scand J Infect Dis 2014;46:704-11. [PMID: 25131415 DOI: 10.3109/00365548.2014.936492] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
41 Yelken B, Caliskan Y, Ozkan O, Gorgulu N, Yazici H, Turkmen A, Sever MS. Conversion to sirolimus in renal transplant recipients: a single-center experience. Artif Organs. 2010;34:E230-E237. [PMID: 20618227 DOI: 10.1111/j.1525-1594.2010.01022.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Fischereder M, Graeb C, Krüger B, Kammerl MC, Zülke C, Jauch KW, Krämer BK. Conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction. Transplant Proc. 2006;38:1295-1297. [PMID: 16797286 DOI: 10.1016/j.transproceed.2006.03.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
43 Wali RK, Weir MR. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? Curr Opin Organ Transplant 2008;13:614-21. [PMID: 19060552 DOI: 10.1097/MOT.0b013e3283193bad] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
44 Abramowicz D, Hadaya K, Hazzan M, Broeders N, Hoang AD, Ghisdal L, Noel C, Wissing KM. Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects. Nephrol Dial Transplant 2008;23:3727-9. [PMID: 18567692 DOI: 10.1093/ndt/gfn332] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
45 Ram Peddi V, Jensik S, Pescovitz M, Pirsch J, Adler SH, Richard Thistlethwaite J, Vincenti F, Cohen DJ. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005;19:130-6. [DOI: 10.1111/j.1399-0012.2004.00314.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
46 Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009;88:135-41. [PMID: 19584693 DOI: 10.1097/TP.0b013e3181aad256] [Cited by in Crossref: 89] [Cited by in F6Publishing: 17] [Article Influence: 7.4] [Reference Citation Analysis]
47 Pascual J, Boletis IN, Campistol JM. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplantation Reviews 2006;20:1-18. [DOI: 10.1016/j.trre.2005.10.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
48 Glanville AR, Morton JM, Aboyoun CL, Plit ML, Malouf MA. Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation. The Journal of Heart and Lung Transplantation 2004;23:1170-4. [DOI: 10.1016/j.healun.2003.08.032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
49 Iriart X, Bouar ML, Kamar N, Berry A. Pneumocystis Pneumonia in Solid-Organ Transplant Recipients. J Fungi (Basel) 2015;1:293-331. [PMID: 29376913 DOI: 10.3390/jof1030293] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
50 Renoult E, Buteau C, Lamarre V, Turgeon N, Tapiero B. Infectious risk in pediatric organ transplant recipients: Is it increased with the new immunosuppressive agents? Pediatric Transplantation 2005;9:470-9. [DOI: 10.1111/j.1399-3046.2005.00325.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
51 Asare K, Gatzke CB. Mycophenolate-induced oral ulcers: Case report and literature review. Am J Health Syst Pharm 2020;77:523-8. [PMID: 32058566 DOI: 10.1093/ajhp/zxz358] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
52 Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 2006;10:474-8. [PMID: 16712606 DOI: 10.1111/j.1399-3046.2006.00503.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
53 Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO. Considerations in sirolimus use in the early and late post-transplant periods. Expert Opinion on Drug Safety 2009;8:421-34. [DOI: 10.1517/14740330903037156] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
54 Lo A, Alloway RR. Strategies to Reduce Toxicities and Improve Outcomes in Renal Transplant Recipients. Pharmacotherapy 2002;22:316-28. [DOI: 10.1592/phco.22.5.316.33198] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
55 Kahan BD, Etheridge WB. Minimization of calcineurin inhibitors: a review of de-novo strategies and conversion algorithms: . Current Opinion in Organ Transplantation 2007;12:624-35. [DOI: 10.1097/mot.0b013e3282f1fbec] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
56 Thervet E, Martinez F, Legendre C. Benefit-Risk Assessment of Ciclosporin Withdrawal in Renal Transplant Recipients: . Drug Safety 2004;27:457-76. [DOI: 10.2165/00002018-200427070-00003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
57 Wu M, Chang C, Hung C. Rapamycin in patients with chronic renal allograft dysfunction. Clin Transplant 2005;19:236-42. [DOI: 10.1111/j.1399-0012.2005.00329.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
58 Ghadimi M, Mohammadpour Z, Dashti-khavidaki S, Milajerdi A. m-TOR inhibitors and risk of Pneumocystis pneumonia after solid organ transplantation: a systematic review and meta-analysis. Eur J Clin Pharmacol 2019;75:1471-80. [DOI: 10.1007/s00228-019-02730-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
59 Sennesael JJ, Bosmans JL, Bogers JP, Verbeelen D, Verpooten GA. Conversion from Cyclosporine to Sirolimus in Stable Renal Transplant Recipients: . Transplantation 2005;80:1578-85. [DOI: 10.1097/01.tp.0000184623.35773.6a] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
60 Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc. 2003;35:209S-216S. [PMID: 12742498 DOI: 10.1016/s0041-1345(03)00217-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 9] [Article Influence: 2.9] [Reference Citation Analysis]
61 Rubin RH. Infection in the Organ Transplant Recipient. In: Rubin RH, Young LS, Van Furth R, editors. Clinical Approach to Infection in the Compromised Host. Boston: Springer US; 2002. pp. 573-679. [DOI: 10.1007/0-306-47527-8_17] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
62 Weir MR. Is chronic calcineurin inhibitor toxicity responsible for long-term deterioration of renal function in transplant recipients? Transplantation Reviews 2003;17:20-30. [DOI: 10.1053/trre.2003.5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
63 Iriart X, Challan Belval T, Fillaux J, Esposito L, Lavergne R, Cardeau-desangles I, Roques O, Del Bello A, Cointault O, Lavayssière L, Chauvin P, Menard S, Magnaval J, Cassaing S, Rostaing L, Kamar N, Berry A. Risk Factors of Pneumocystis Pneumonia in Solid Organ Recipients in the Era of the Common Use of Posttransplantation Prophylaxis: Risk Factors of PCP in SOT Patients. American Journal of Transplantation 2015;15:190-9. [DOI: 10.1111/ajt.12947] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 9.9] [Reference Citation Analysis]
64 Gupta P, Kaufman S, Fishbein TM. Sirolimus for solid organ transplantation in children. Pediatric Transplantation 2005;9:269-76. [DOI: 10.1111/j.1399-3046.2005.00305.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
65 Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of Success in Conversion from Calcineurin Inhibitor to Sirolimus in Chronic Allograft Dysfunction. Am J Transplant 2004;4:1869-75. [DOI: 10.1111/j.1600-6143.2004.00590.x] [Cited by in Crossref: 204] [Cited by in F6Publishing: 165] [Article Influence: 12.0] [Reference Citation Analysis]
66 Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant. 2008;22:1-15. [PMID: 18217899 DOI: 10.1111/j.1399-0012.2007.00739.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 50] [Article Influence: 0.8] [Reference Citation Analysis]
67 Lennon A, Finan K, FitzGerald MX, McCormick PA. Interstitial pneumonitis associated with sirolimus (rapamycin) therapy after liver transplantation. Transplantation. 2001;72:1166-1167. [PMID: 11579321 DOI: 10.1097/00007890-200109270-00034] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
68 Montalbano M, Neff GW, Yamashiki N, Meyer D, Bettiol M, Slapak-green G, Ruiz P, Manten E, Safdar K, O’brien C, Tzakis AG. A Retrospective Review of Liver Transplant Patients Treated with Sirolimus from a Single Center: An Analysis of Sirolimus-Related Complications. Transplantation 2004;78:264-8. [DOI: 10.1097/01.tp.0000128628.31556.b1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
69 Oz HS, Hughes WT, Varilek G. Provocative effects of the immunosuppressants rapamycin, tacrolimus, and dexamethasone on pneumonitis in contrast to the anti- pneumonitis effects of mycophenolate mofetil. Transplantation 2001;72:1464-5. [PMID: 11685124 DOI: 10.1097/00007890-200110270-00025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
70 Almeida M, Martins L, Dias L, Figueiredo M, Henriques A, Sarmento A, Cabrita A. Conversion to Sirolimus in a Population of Kidney and Kidney-Pancreas Transplant Recipients. Transplantation Proceedings 2005;37:2777-80. [DOI: 10.1016/j.transproceed.2005.06.088] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
71 Burdmann EA, Bennett WM. Nephrotoxicity of calcineurin and mTOR inhibitors. In: De Broe ME, Porter GA, Bennett WM, Deray G, editors. Clinical Nephrotoxins. Boston: Springer US; 2008. pp. 617-82. [DOI: 10.1007/978-0-387-84843-3_28] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
72 MacDonald AS. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant Proc 2003;35:201S-8S. [PMID: 12742497 DOI: 10.1016/s0041-1345(03)00231-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
73 Murugan AK. mTOR: Role in cancer, metastasis and drug resistance. Semin Cancer Biol 2019;59:92-111. [PMID: 31408724 DOI: 10.1016/j.semcancer.2019.07.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 54] [Article Influence: 33.0] [Reference Citation Analysis]
74 Patel SJ, Dawson KL, Knight RJ, Abdellatif A, Achkar K, Gaber LW, Gaber AO. The role of mTOR inhibition in renal transplant immune suppression. Dial Transplant 2011;40:23-9. [DOI: 10.1002/dat.20530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Danovitch GM. How should the immunosuppressive regimen be managed in patients with established chronic allograft failure? Kidney International 2002;61:S68-72. [DOI: 10.1046/j.1523-1755.61.s80.12.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
76 Toper C, Rivaud E, Daniel C, Cerf C, Parquin F, Catherinot É, Honderlick P, Escande M, Dreyfus J, Stern M, Couderc L. Pneumocystose pulmonaire chez des patients immunodéprimés non infectés par le VIH : étude de 41 cas. Revue de Pneumologie Clinique 2011;67:191-8. [DOI: 10.1016/j.pneumo.2011.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
77 Catherinot E, Lanternier F, Bougnoux ME, Lecuit M, Couderc LJ, Lortholary O. Pneumocystis jirovecii Pneumonia. Infect Dis Clin North Am. 2010;24:107-138. [PMID: 20171548 DOI: 10.1016/j.idc.2009.10.010] [Cited by in Crossref: 134] [Cited by in F6Publishing: 96] [Article Influence: 12.2] [Reference Citation Analysis]
78 Saber LS, Ikeda M, Almeida J. Posttransplantation Conversion to Sirolimus-Based Immunosuppression: A Single Center Experience. Transplantation Proceedings 2007;39:3098-100. [DOI: 10.1016/j.transproceed.2007.04.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
79 Kuypers DRJ. Benefit-Risk Assessment of Sirolimus in Renal Transplantation: . Drug Safety 2005;28:153-81. [DOI: 10.2165/00002018-200528020-00006] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 4.6] [Reference Citation Analysis]
80 Martinez-mier G, Avila-pardo SF, Mendez-lopez MT, Budar-fernandez LF. Long-term results after conversion from calcineurin inhibitors to sirolimus in renal transplant patients: Sirolimus conversion in renal transplant patients. Clinical Transplantation 2010;24:467-73. [DOI: 10.1111/j.1399-0012.2009.01082.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
81 Böhler T, Waiser J, Lichter S, Schumann B, Neumayer HH, Kamar N, Budde K. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients. Cytokine. 2008;42:306-311. [PMID: 18440821 DOI: 10.1016/j.cyto.2008.02.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
82 Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies: . Current Opinion in Critical Care 2001;7:384-9. [DOI: 10.1097/00075198-200112000-00003] [Cited by in Crossref: 225] [Cited by in F6Publishing: 193] [Article Influence: 11.3] [Reference Citation Analysis]
83 Isaacs RB. Optimal transplant immunosuppression: A case of the haves and have nots? American Journal of Kidney Diseases 2001;37:160-3. [DOI: 10.1016/s0272-6386(01)80072-x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
84 Egidi M, Cowan P, Naseer A, Gaber A. Conversion to sirolimus in solid organ transplantation: a Single-Center experience. Transplantation Proceedings 2003;35:S131-7. [DOI: 10.1016/s0041-1345(03)00240-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
85 Citterlo F, Scatà MC, Violi P, Romagnoli J, Pozzetto U, Nanni G, Castagneto M. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc. 2003;35:1292-1294. [PMID: 12826140 DOI: 10.1016/s0041-1345(03)00375-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
86 Weber T, Abendroth D, Schelzig H. Rapamycin rescue therapy in patients after kidney transplantation: first clinical experience. Transplant Int 2005;18:151-6. [DOI: 10.1111/j.1432-2277.2004.00032.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]